Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Esperion Therapeutics’ regulatory disclosures blend dense cardiovascular science with intricate royalty agreements. Searching a 300-page 10-K for bempedoic acid sales projections or scanning Form 4s to see when executives exercise options can take hours. That’s exactly why investors ask, "Where can I find Esperion Therapeutics' quarterly earnings report 10-Q filing?" or "How do I track Esperion Therapeutics insider trading Form 4 transactions in real time?" Stock Titan answers in seconds.
Our platform delivers AI-powered summaries so you can start understanding Esperion Therapeutics SEC documents with AI rather than reading line by line. Real-time alerts surface Esperion Therapeutics Form 4 insider transactions real-time, while side-by-side comparisons turn each Esperion Therapeutics quarterly earnings report 10-Q filing into an at-a-glance trend chart. Need the story behind a sudden milestone payment? Our AI links the related Esperion Therapeutics 8-K material events explained to management commentary, giving context that traditional databases miss. And because we track every form—10-K, 10-Q, 8-K, Form 4, S-1, DEF 14A—you never miss a disclosure.
You’ll also get a simplified view of the Esperion Therapeutics annual report 10-K simplified, a deep dive into the Esperion Therapeutics proxy statement executive compensation, and an Esperion Therapeutics earnings report filing analysis that highlights R&D spending on next-generation LDL-C therapies. Every document—from insider trading Form 4s to 8-K clinical-trial updates—arrives within moments of hitting EDGAR. Stop piecing together fragments; rely on Stock Titan’s expert analysis to see the full picture of Esperion’s drug commercialization, cash runway, and Esperion Therapeutics executive stock transactions Form 4 in one place.
Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 9,954,975 shares of Esperion Therapeutics common stock, representing 5.0% of the class based on 198,199,462 shares outstanding. The shares are held by Two Seas Global (Master) Fund LP, for which Two Seas Capital acts as investment adviser and has sole voting and dispositive power; TSC GP and Mr. Toussi are identified through their general partner and managing member roles.
The filing states the position is held in the ordinary course of business and not to change or influence control of the issuer. The disclosure quantifies position size and control over voting and disposition rights without indicating an intent to seek corporate control.
Esperion Therapeutics has registered an additional 6,250,000 shares of its common stock for issuance under the company’s 2022 Stock Option and Incentive Plan, as amended, following stockholder approval of the plan amendment on May 29, 2025. The Registration Statement on Form S-8 incorporates prior Form S-8 registration statements for the same class of securities.
This filing enables the company to grant additional equity awards under its incentive plan; it is a routine corporate step to implement the expanded reserve and does not itself change outstanding shares until awards are issued and exercised.
Esperion Therapeutics reported continued U.S. commercial momentum for its oral, non‑statin LDL‑C medicines as product sales rose to $40.3 million in Q2 2025 and $75.2 million for the six months ended June 30, 2025, up from $28.3 million and $53.1 million in the comparable 2024 periods, indicating stronger prescriptions and channel activity.
Collaboration revenue was approximately $42.1 million in Q2 2025 and $72.2 million year‑to‑date, down from $158.5 million for the prior six‑month period largely because prior‑year results included larger milestone recognition. Cash and cash equivalents declined to $86.1 million at June 30, 2025 from $144.8 million at December 31, 2024. Total assets were $347.1 million and total liabilities increased to $780.6 million, resulting in a stockholders' deficit of $(433.5) million.
The company recognized notable finance and capital transactions: proceeds from a $304.7 million sale of future DSE royalties are recorded as a royalty sale liability of approximately $295.9 million (net of issuance costs), and it maintains long‑term debt from a $150.0 million term loan with a carrying amount of $146.5 million. Interest expense increased year‑over‑year and contributed to a consolidated net loss of $53.18 million for the six months ended June 30, 2025. Esperion settled patent disputes with three ANDA filers who agreed not to market a generic version of NEXLETOL in the U.S. before April 19, 2040, while litigation against remaining ANDA filers continues.
Esperion Therapeutics, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 because it has not completed its quarter-end financial close. Management identified errors in an earnings release previously furnished and subsequently amended; the amended release contains preliminary, unaudited financial data based on management estimates that remain subject to completion of closing procedures. The Company requires additional time to finalize its condensed financial statements.
Esperion states it expects to file the Form 10-Q as soon as practicable and no later than the five-calendar-day extension permitted by Rule 12b-25. The filing notes that all other periodic reports for the last 12 months have been filed and that the Company does not anticipate a significant change in results versus the comparable prior-year period. Contact: Sheldon L. Koenig, President and CEO.
Esperion Therapeutics filed an Amendment No. 1 to its Form 8-K to correct its August 5, 2025 earnings release. The amendment corrects the Balance Sheet Data for the period ended June 30, 2025 and the Statement of Operations for the three and six months ended June 30, 2025, specifically net income (loss), net income (loss) per share, and income from operations for the three-month period. A corrected earnings release is furnished as Exhibit 99.1 dated August 11, 2025. Management states these figures are preliminary, unaudited, and subject to completion of the quarter-end close and may change; all other disclosures remain unchanged.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
